Literature DB >> 6357268

Fractionated total body irradiation in marrow transplantation for leukaemia.

V Vitale, A Bacigalupo, M T Van Lint, F Frassoni, G Ricci, G Siracusa, G Marziano, M L Vitali, G Scielzo, A Tomassini.   

Abstract

Thirty consecutive patients with leukaemia were prepared for bone marrow transplantation (BMT) with cyclophosphamide (CY) 120 mg/kg followed by total body irradiation (TBI). TBI was delivered in a single dose (sTBI) of 10 Gy, at a dose rate of 0.06-0.08 Gy/min, or in fractionated doses (fTBI) of 3.3 Gy/d, on each of 3 consecutive days, at the same dose rate. Lung shielding was adopted for all patients, in order to obtain a homogeneous dose delivered to the lung and at midline. The first 12 patients were prepared with sTBI and the following 18 with fTBI. Several variables (remission status, mode of irradiation, prevention of graft versus host disease (GvHD) with methotrexate (MTX) or cyclosporin A(CyA) were then analysed for their influence on (a) incidence and mortality of GvHD, (b) incidence and mortality of interstitial pneumonia (IP), (c) 100-d survival, and (d) relapses. Our data suggest that fTBI is the single most important factor associated with a lower incidence of IP (P = 0.002), a lower mortality from GvHD and IP (P = 0.03 and 0.001) and a better 100-d survival (P = 0.03). Remission status had no significant influence on GvHD, IP and acute mortality. When compared to MTX, the use of CyA was associated with less GvHD and IP, but when only patients in remission given fTBI were analysed, this was no longer true. Relapses were mostly influenced by the remission status of the patient at transplant (P = 0.001). Although this is not a randomized study, our data suggest that fTBI can reduce the acute risks of marrow transplantation in leukaemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357268     DOI: 10.1111/j.1365-2141.1983.tb02169.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Effect of once-a-day fractionated total body irradiation on the risk of relapse after non-T-cell-depleted HLA-matched sibling transplantation.

Authors:  Tarek Ben Othman; Lotfi Kochbati; Abderrahman Abdelkefi; Saloua Ladeb; Lamia Torjman; Amel Lakhal; Leila Kammoun; Dalenda Hentati; Mounir Besbes; Abdeladhim Ben Abdeladhim; Mongi Maalej
Journal:  Radiat Med       Date:  2007-10-26

2.  Total Body Irradiation-Based Conditioning Regimen Improved the Survival of Adult Patients With T-Cell Lymphoblastic Lymphoma After Allogeneic Peripheral Blood Stem Cell Transplantation.

Authors:  Jiahua Niu; Zhixiao Chen; Jie Gao; Huiying Qiu; Liping Wan; Ying Wang; Wenwei Wang; Yin Tong; Chongmei Huang; Yu Cai; Xiaowei Xu; Kun Zhou; Ying Zhang; Xinxin Xia; Chang Shen; Yu Wei; Tingfeng Chen; Xianmin Song; Jun Yang
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

Review 3.  Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions.

Authors:  Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht
Journal:  Front Pediatr       Date:  2021-12-03       Impact factor: 3.418

4.  Once-a-day fractionated total-body irradiation: A regimen tailored to local logistics in allogeneic stem cell transplantation for acute lymphoblastic leukemia.

Authors:  Nour Ben Abdeljelil; Saloua Ladeb; Talel Dahmani; Lotfi Kochbati; Amel Lakhal; Rym El Fatmi; Lamia Torjemane; Dorra Belloumi; Mounir Besbes; Farouk El Benna; Chiraz Nasr Ben Ammar; Tarek Ben Othman
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-28

5.  Lung diseases after bone marrow transplantation. Results of a clinical, radiological, histological, immunological and lung function study.

Authors:  H Link; U Reinhard; E Walter; P Wernet; E M Schneider; H Fischbach; M Blaurock; K Wilms; D Niethammer; P Ostendorf
Journal:  Klin Wochenschr       Date:  1986-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.